
Extranodal natural killer/T-cell lymphoma (NKTCL) is an aggressive lymphoma characterized by a strong association with Epstein–Barr virus (EBV) and substantial biological heterogeneity. As our understanding of the mechanisms underlying disease development and progression continues to deepen, and therapeutic strategies such as asparaginase and immune checkpoint inhibitors are increasingly explored, the treatment landscape of NKTCL is undergoing profound changes. Identifying new therapeutic targets based on disease pathogenesis and translating basic research findings into clinical practice have become important priorities for further improving patient outcomes.
Recently, Dr. Jie Xiong of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, delivered a systematic presentation entitled “Extranodal NK/T-Cell Lymphoma: From Fatal to Curable.” He discussed the molecular pathogenesis, metabolic abnormalities, tumor immune microenvironment, and molecular classification of NKTCL, and shared his team’s translational research in the treatment of early-stage, advanced-stage, and relapsed/refractory NKTCL. His presentation illustrated a research pathway extending from mechanistic discoveries to precision treatment.
Uncovering the Molecular Basis of NKTCL Development Through Mechanistic Research
The development and progression of NKTCL involve multiple layers of molecular abnormalities, including disruption of genomic homeostasis, metabolic reprogramming, dysregulation of the immune microenvironment, and epigenetic alterations. Focusing on these key biological characteristics, Professor Weili Zhao, Dr. Jie Xiong, and their team have conducted a series of studies that have gradually elucidated the molecular basis of NKTCL pathogenesis.
The synergistic effects of DDX3X mutations and EBV contribute to genomic instability.
DDX3X is the most frequently mutated gene in NKTCL, with a mutation rate of approximately 20%. It belongs to the RNA helicase family and also has functions associated with tumor suppressor genes. Further investigations by the team revealed that the EBV-encoded protein BNLF2b is highly expressed in tumor cells harboring DDX3X mutations. The combined effects of these two factors can lead to abnormal R-loop accumulation, subsequently disrupting genomic homeostasis.
By developing a transgenic mouse model combining DDX3X mutations with BNLF2b expression, the research team observed corresponding malignant phenotypes and malignant transformation of NK lymphocytes, further supporting the role of their synergistic effects in NKTCL development and progression. Based on these findings, the team also investigated the potential of the RNA polymerase II inhibitor etoposide to intervene in the associated molecular abnormalities, providing a research basis for identifying therapeutic opportunities through targeting genomic homeostasis.
MGA mutations reveal a novel mechanism regulating tumor stemness.
In addition to DDX3X, the team has also focused on abnormalities involving genes such as MGA. Using a conditional MGA-knockout mouse model, the researchers found that MGA deficiency can induce stemness-associated phenotypes in malignant lymphocytes. They have subsequently investigated the underlying molecular mechanisms and potential targeted therapeutic approaches. This research provides new insights into the molecular heterogeneity of NKTCL and the mechanisms driving the persistent malignant proliferation of tumor cells.
Targeting Metabolic Vulnerabilities and the Immune Microenvironment to Expand Opportunities for Precision Treatment
In addition to genomic abnormalities, metabolic reprogramming is another important biological feature of NKTCL. The team’s research identified pronounced abnormalities in glutamine metabolism in NKTCL cells, with the amino acid transporter SLC1A1/EAAT3 playing an important role.
Through RNA sequencing, metabolomics, and stable isotope tracing, the team elucidated the dependence of NKTCL cells on glutamine metabolism and identified the involvement of SLC1A1/EAAT3 in regulating glutamine uptake and related metabolic processes. Further investigations suggested that abnormal glutamine metabolism not only supports the malignant biological behavior of tumor cells but is also closely associated with tumor immune regulation.
Building on this metabolic vulnerability, the team explored the therapeutic value of asparaginase, providing a theoretical basis for exploiting the metabolic dependencies of NKTCL cells as a treatment strategy. SLC1A1/EAAT3 has also shown potential as a prognostic biomarker.
Extending metabolic research from tumor cells to T-cell exhaustion.
The team further discovered a close relationship between abnormal glutamine metabolism and the tumor immune microenvironment. The metabolic state of tumor cells may influence CD8+ T-cell function and contribute to immunosuppression and immune exhaustion. This suggests that the value of metabolic-targeted therapy may extend beyond directly interfering with tumor cells: by modulating interactions between tumor cells and immune cells, it may also help improve the antitumor immune response.
EBV-mediated regulation of the tumor immune microenvironment provides new immunotherapeutic targets.
EBV is an important driver of NKTCL development and progression. Through single-cell localization of EBV, analysis of viral gene expression, and investigation of protein interaction networks in tumor tissues, the team further elucidated how EBV regulates the NKTCL tumor immune microenvironment.
The researchers found that EBV-related signaling may participate in tumor immune regulation through G protein-coupled receptors (GPCRs), with CCR1-mediated immune exhaustion representing a particularly important mechanism. This finding links EBV-associated pathogenic mechanisms with immune checkpoint regulation and provides a basis for exploring new immunotherapeutic targets.
From Mechanistic Discoveries to Clinical Practice: Continuously Optimizing NKTCL Treatment Strategies
The ultimate value of basic research lies in its translation into clinical practice. Addressing the treatment needs of patients at different stages of NKTCL, Professor Weili Zhao, Dr. Jie Xiong, and their team have conducted a series of clinical studies, gradually exploring treatment strategies based on the biological characteristics of the disease.
01. Early-Stage NKTCL: Optimizing Chemotherapy Regimens and Exploring Precision Risk Stratification
The introduction of the SMILE regimen once represented an important milestone in NKTCL treatment. In a study involving 38 patients with newly diagnosed stage IV or relapsed/refractory NKTCL, the SMILE regimen achieved an overall response rate (ORR) of 79% and a complete response rate (CRR) of 45%, with a 1-year overall survival (OS) rate of 45%. These findings helped advance the application of asparaginase-based treatment strategies in NKTCL.
Building on this progress, the team conducted a study of the MESA regimen—methotrexate, etoposide, dexamethasone, and pegaspargase—with sandwich radiotherapy for early-stage NKTCL. The results showed a 2-year progression-free survival (PFS) rate of 89.1% and a 2-year OS rate of 92.0%, providing a new direction for the comprehensive treatment of early-stage NKTCL.
The team subsequently conducted a comparative study of MESA and ESA (etoposide, dexamethasone, and pegaspargase). Long-term follow-up data showed 5-year PFS rates of 74.9% and 80.3%, respectively, and 5-year OS rates of 80.9% and 85.1%, respectively. The study also demonstrated that achieving complete response at the interim assessment and having undetectable plasma EBV DNA were associated with better clinical outcomes, with a 2-year PFS rate of 93%. These findings further suggest that dynamic assessment incorporating imaging response and EBV DNA status during treatment can help identify patient populations with different prognostic risks, providing a basis for risk-adapted treatment in early-stage NKTCL.
02. Advanced-Stage NKTCL: Exploring Immunotherapy Combinations to Improve Long-Term Survival
For advanced-stage NKTCL, the team explored the combination of an anti-PD-1 antibody and pegaspargase. The study reported a complete response rate of 59% and an ORR of 68%. The 2-year and 5-year PFS rates were 72.7% and 59.1%, respectively, while the corresponding OS rates reached 86.1% and 76.5%. These findings suggest that combining asparaginase with immune checkpoint inhibitors may provide durable benefits for patients with advanced-stage NKTCL and offer clinical evidence supporting further investigation of immunotherapy-based combinations.
Building on this work, the team designed a randomized controlled study in patients with newly diagnosed stage III–IV NKTCL to compare the efficacy of pegaspargase combined with a PD-1 antibody and chidamide against the DDGP regimen. Interim and end-of-treatment PET assessments are incorporated to guide subsequent treatment decisions. For patients who do not achieve a response, second-line clinical studies are being further explored, with the aim of establishing a more dynamic and individualized treatment pathway for advanced-stage NKTCL.
Addressing Disease Heterogeneity and Relapsed/Refractory NKTCL: Exploring Next-Generation Precision Treatment Strategies
NKTCL is not a single biological entity. Patients differ in cellular origin, molecular characteristics, immune microenvironment, and clinical outcomes. Through multidimensional investigations involving T-cell receptor (TCR) rearrangement, immunohistochemistry, fluorescence in situ hybridization (FISH), and transcriptomic analysis, Professor Weili Zhao, Dr. Jie Xiong, and their team have further elucidated the cellular origin and molecular heterogeneity of NKTCL.
For molecular classification, the team integrated transcriptomic and genomic data and identified distinct oncogenic signaling pathways and immune pathway activation profiles across different molecular subtypes. Among these, the immune-desert phenotype and the MB subtype were associated with poor prognosis. These findings suggest that future NKTCL treatment should move beyond a uniform therapeutic approach and incorporate molecular subtyping, immune characteristics, and clinical risk to achieve more precise patient stratification and treatment optimization.
The team is also actively exploring novel combination strategies for relapsed/refractory NKTCL. Dr. Xiong introduced two ongoing clinical studies. One is investigating P-GemOx (pegaspargase, gemcitabine, and oxaliplatin) combined with a PD-1 antibody and selinexor; the other is evaluating golidocitinib combined with a PD-1 antibody and selinexor. Both studies incorporate PET-based response assessment, with subsequent consideration of autologous hematopoietic stem cell transplantation, consolidation therapy, or allogeneic hematopoietic stem cell transplantation according to treatment response. These studies offer new avenues for therapeutic exploration in patients with relapsed/refractory disease.
In addition, the team particularly emphasized the prognostic significance of persistent EBV viremia. In both early- and advanced-stage NKTCL, persistent EBV viremia is associated with poor prognosis. Therefore, serial monitoring of plasma EBV DNA may not only help assess treatment response but also provide important information for identifying relapse risk and guiding subsequent treatment decisions.
Regarding EBV-targeted treatment, Dr. Xiong also introduced the EBV mRNA vaccine WGc-043 injection and a Phase I clinical study of KSD-101 for EBV-associated hematologic malignancies. These investigations offer new possibilities for developing novel therapeutic strategies based on EBV-related pathogenic mechanisms.
Conclusion
From the disruption of genomic homeostasis mediated by the synergistic effects of DDX3X mutations and EBV, to glutamine metabolic dependence involving SLC1A1/EAAT3, and the regulation of the tumor immune microenvironment through the EBV–CCR1 axis, Professor Weili Zhao, Dr. Jie Xiong, and their team have conducted systematic research into key pathogenic mechanisms of NKTCL and continuously advanced the translation of basic discoveries into clinical treatment.
From risk stratification and comprehensive treatment for patients with early-stage disease, to immunotherapy combinations for advanced-stage disease, and the exploration of novel targeted regimens for relapsed/refractory disease, the therapeutic approach to NKTCL is gradually shifting from conventional chemotherapy toward mechanism-driven, molecular subtype-guided precision treatment.
The transition “from fatal to curable” means more than simply expanding the range of available treatments. It reflects a deeper understanding of the disease itself and the continued integration of basic research, clinical studies, and individualized treatment. As further mechanistic discoveries are validated and clinical trials continue to advance, patients with NKTCL may have access to increasingly precise, effective, and durable treatment options.
Expert Profile

Dr. Jie Xiong
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Attending Physician, Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Associate Researcher, Shanghai Institute of Hematology; Master’s Supervisor
- Young Talent, Shanghai Oriental Talent Program
- Young Medical Talent, Shanghai Rising-Star Program for Medical Professionals
- Recipient of the Shanghai Science and Technology Commission’s Rising-Star Program (Category A)
- Selected for the Shanghai Science and Technology Youth 35 Leaders Program
- Recipient of the Shanghai Municipal Education Commission’s Chen Guang Program
Dr. Xiong has led multiple General and Young Scientists Program projects funded by the National Natural Science Foundation of China, as well as research projects supported by the Shanghai Science and Technology Commission, Shanghai Municipal Education Commission, and Shanghai Municipal Health Commission.
His primary research interests include the molecular mechanisms underlying the pathogenesis of NK/T-cell lymphoma and precision-targeted therapies. He has published numerous SCI-indexed papers as first or corresponding author in leading international journals, including CA: A Cancer Journal for Clinicians, Cancer Cell, Signal Transduction and Targeted Therapy, and Blood.
